Zimbabwe has declined a significant American health deal worth $367m (£272m) spanning five years because of the United States' request for sensitive data.
This rejection was revealed following a official document dated December was leaked, revealing that President Emmerson Mnangagwa deemed the agreement was "skewed".
An official spokesperson has since clarified that the US was seeking biological samples for scientific study and commercial gain while was unwilling to share the benefits from any future medical innovations.
"We will now turn to the challenging and unfortunate process of winding down our support in Zimbabwe," remarked American envoy to Zimbabwe Pamela Tremont in a statement.
The US Embassy noted the United States had provided over $1.9bn in health funding to Zimbabwe over the last twenty years.
A physicians' group in Zimbabwe has urged continued dialogue to find a agreement acceptable to both sides so the country's critical HIV treatment initiative can be sustained.
Wider Implications
This rejection comes after a comparable case in neighbouring Kenya, where a high court suspended a similar deal with the US after concerns were filed about the safety of citizens' health data.
Since returning to office last year, US President Donald Trump has slashed foreign aid and shut down the key foreign aid agency.
USAID had overseen assistance for the US government, but Trump claimed its spending was "wasteful" and his government was seeking direct bilateral deals to boost openness and responsibility.
As per reports, Sixteen nations in Africa have so far agreed to these new health pacts, constituting over $18.3bn of fresh investment.
Specifics of the Declined Agreement
This assistance for Zimbabwe was intended to funded "combating HIV/Aids, TB, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"We believe this collaboration would have delivered immense benefits for Zimbabwean communities, particularly the 1.2 million men, women and children currently receiving HIV treatment through US-supported programmes," Tremont said.
However, official spokesman Nick Mangwana argued the arrangement was "asymmetrical".
"Our nation was requested to surrender its biological resources and data over an extended period, without any equivalent guarantee of benefiting from any scientific breakthroughs – such as new medicines or tests – that could be developed from that shared data," Mangwana explained.
"Effectively, our country would supply the basic resources for scientific discovery without any certainty that the resulting innovations would be accessible to our citizens if a future pandemic emerge."
National Interest and International Frameworks
He also said that the American exit from the World Health Organization (WHO) and its push of one-on-one health agreements were undermining structures previously set up via the international organization.
Mangwana cited its Pathogen Access and Benefit Sharing scheme created to manage potential pandemics.
"This system is designed to guarantee that when a country provides its samples, the benefits – such as vaccines and treatments – are distributed fairly, not commercialised exclusively by those with the capability to create them."
Zimbabwe's reservations over the US deal "must not be interpreted as opposition to America," he added.
"We encourage continued dialogue with our American counterparts on how future co-operation might be designed in a manner that respects the independence and interests of both nations."
Medical Community Reaction
A leading public health body expressed it recognised the official position, but recommended that negotiations must proceed given that a large portion of the nation's HIV programmes were funded by foreign aid.
"Where specific concerns exist, including those relating to information security or implementation frameworks, these can frequently be resolved via detailed discussion and negotiated safeguards," the group commented.
The situation underscores the ongoing debate between accepting crucial foreign assistance and protecting a country's data in an ever more data-driven world.